Experience

Curie.Bio

• United States
• Biotechnology Research
• 1 - 100 Employee

• Drug Maker in Residence

  • Jul 2023 - Present



Schrödinger

• United States
• Software Development
• 700 & Above Employee

• Director

  • Jul 2022 - Jul 2023

• Senior Principal Scientist

  • Jan 2021 - Jul 2022

  Biology lead for wholly owned and collaborative oncology drug discovery programs from hit identification through lead optimization and candidate selection Design, management, and execution of program screening cascade and strategy including primary biochemical/biophysical assays, cellular target engagement and efficacy assays, MOA exploration/validation, indication selection, and in vivo PK/PD and efficacy studies CRO management for assay development and… Show more Biology lead for wholly owned and collaborative oncology drug discovery programs from hit identification through lead optimization and candidate selection Design, management, and execution of program screening cascade and strategy including primary biochemical/biophysical assays, cellular target engagement and efficacy assays, MOA exploration/validation, indication selection, and in vivo PK/PD and efficacy studies CRO management for assay development and implementation. Novel target identification and strategy

• Principal Scientist

  • Apr 2019 - Jan 2021



Bristol Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Research Investigator

  • Jun 2018 - Mar 2019

  Managed an industry leading panel of kinase assays that delivered compound inhibition data for up to 500 compounds in over 250 kinase assays every week for SAR and selectivity screening. Oversaw assay development, weekly panel execution, and data analysis and delivery supporting up to ten active kinase drug discovery programs. Supported drug discovery programs in a wide range of target classes with in-depth biochemical data across all therapeutic areas at Bristol-Myers… Show more Managed an industry leading panel of kinase assays that delivered compound inhibition data for up to 500 compounds in over 250 kinase assays every week for SAR and selectivity screening. Oversaw assay development, weekly panel execution, and data analysis and delivery supporting up to ten active kinase drug discovery programs. Supported drug discovery programs in a wide range of target classes with in-depth biochemical data across all therapeutic areas at Bristol-Myers Squibb. Managed a group of six direct reports working in diverse areas including kinase screening, biochemical and cellular assay development and execution, and technology/platform development and automation

• Research Investigator

  • Feb 2016 - Jun 2018



Princeton University

• United States
• Higher Education
• 700 & Above Employee

• PhD Candidate

  • May 2010 - Nov 2015

  Thesis: Molecular Mechanisms of Signaling in the ERK MAP Kinase Pathway Mapped the binding interface of ERK and transcriptional repressor Capicua using a novel technique involving photocrosslinking with a noncanonical amino acid and analysis by mass spectrometry. Capicua plays important roles in development and has been implicated in a number of human diseases. Studied the effects of clinically relevant mutations in MEK, the enzyme responsible for activating the ERK MAP Kinase… Show more Thesis: Molecular Mechanisms of Signaling in the ERK MAP Kinase Pathway Mapped the binding interface of ERK and transcriptional repressor Capicua using a novel technique involving photocrosslinking with a noncanonical amino acid and analysis by mass spectrometry. Capicua plays important roles in development and has been implicated in a number of human diseases. Studied the effects of clinically relevant mutations in MEK, the enzyme responsible for activating the ERK MAP Kinase. Used mass spectrometry to track the kinetics of activating phosphorylation reactions in multiple levels of regulation. The MEK mutants studied were discovered in patients suffering from cancer and RASopathies, a class of developmental disorders caused by mutations in MAP Kinase pathway components. Show less Thesis: Molecular Mechanisms of Signaling in the ERK MAP Kinase Pathway Mapped the binding interface of ERK and transcriptional repressor Capicua using a novel technique involving photocrosslinking with a noncanonical amino acid and analysis by mass spectrometry. Capicua plays important roles in development and has been implicated in a number of human diseases. Studied the effects of clinically relevant mutations in MEK, the enzyme responsible for activating the ERK MAP Kinase… Show more Thesis: Molecular Mechanisms of Signaling in the ERK MAP Kinase Pathway Mapped the binding interface of ERK and transcriptional repressor Capicua using a novel technique involving photocrosslinking with a noncanonical amino acid and analysis by mass spectrometry. Capicua plays important roles in development and has been implicated in a number of human diseases. Studied the effects of clinically relevant mutations in MEK, the enzyme responsible for activating the ERK MAP Kinase. Used mass spectrometry to track the kinetics of activating phosphorylation reactions in multiple levels of regulation. The MEK mutants studied were discovered in patients suffering from cancer and RASopathies, a class of developmental disorders caused by mutations in MAP Kinase pathway components. Show less